Evenity (Romosozumab) Overdose and Accidental Excess Dose

At a glance

• Generic name / brand / Approved dose: romosozumab / Evenity / 210 mg subcutaneous monthly for 12 months
• Overdose antidote / No specific antidote exists; treatment is supportive
• Phase I maximum tested dose / 10 mg/kg IV (roughly 5x the labeled exposure) without dose-limiting toxicity
• Primary overdose risk / Hypocalcemia, especially in vitamin D-deficient patients
• Cardiovascular boxed warning / Increased MACE risk observed in ARCH; monitor after excess dosing
• Half-life / Approximately 12.8 days after 210 mg SC
• Dialyzability / Not expected to be removed by dialysis due to large molecular weight (~149 kDa)
• Accidental double dose advice / Skip the next monthly dose; resume normal schedule
• Post-marketing fatal overdose reports / None documented as of 2026
• FDA approval year / 2019 for osteoporosis in postmenopausal women at high fracture risk

Why Romosozumab Overdose Is Clinically Uncommon but Not Impossible

Romosozumab is administered as two subcutaneous injections of 105 mg each (totaling 210 mg) once monthly in a healthcare setting or at home after training. The fixed-dose prefilled syringe format limits accidental mega-doses. Overdose scenarios typically involve an inadvertent second monthly dose given too early, either because of a scheduling error at the clinic or patient confusion about injection timing.

The FDA-approved prescribing information states plainly: "There is no experience with overdosage of romosozumab-aqqg." No dose-dependent organ toxicity signal appeared in Phase I trials that tested intravenous doses up to 10 mg/kg, a systemic exposure roughly five times greater than the labeled 210 mg subcutaneous dose [1]. This absence of toxicity data at supratherapeutic levels means management is supportive rather than protocol-driven. Clinicians should focus on monitoring serum calcium, cardiac symptoms, and injection-site reactions.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines on osteoporosis management do not include a specific overdose algorithm for romosozumab but recommend vigilant monitoring of calcium homeostasis throughout the 12-month treatment course [2]. Patients on concurrent calcium and vitamin D supplementation have an added safety margin.

How Romosozumab Works: The Sclerostin Inhibition Mechanism

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced primarily by osteocytes. Sclerostin normally acts as a brake on the Wnt signaling pathway in bone. When romosozumab neutralizes sclerostin, two things happen simultaneously: osteoblast-mediated bone formation accelerates, and osteoclast-driven bone resorption decreases [3]. This dual effect distinguishes it from every other approved osteoporosis therapy.

The bone formation marker P1NP rises sharply within the first month of treatment, peaks around month 6, and then gradually returns toward baseline by month 12. Bone resorption markers (CTX) decline rapidly and remain suppressed throughout the 12-month course [4]. This time-dependent pharmacodynamic profile matters for overdose assessment. A patient who receives an extra dose early in treatment (months 1 through 3) will experience this effect on a background of already-elevated bone turnover markers. A patient who accidentally doubles a dose near month 10 or 11 does so when the anabolic window is already closing.

The antibody's molecular weight is approximately 149 kDa. Large molecules like this distribute primarily in the vascular and interstitial compartments rather than crossing the blood-brain barrier or accumulating in hepatic tissue, which partly explains the absence of central nervous system or hepatotoxic signals even at supratherapeutic exposures [1].

Phase I Dose-Escalation Data: The Best Evidence We Have for Overdose Safety

The Phase I first-in-human study (Padhi et al., 2011) enrolled 72 healthy postmenopausal women and tested single ascending doses of romosozumab from 0.1 mg/kg to 10 mg/kg intravenously and 1 mg/kg to 3 mg/kg subcutaneously [1]. At 10 mg/kg IV, the peak serum concentration was more than five times higher than what 210 mg SC produces.

No serious adverse events occurred at any dose level. The most common side effects were mild injection-site erythema and headache, both self-limited. Serum calcium declined modestly in a dose-dependent fashion, with the largest transient drop of approximately 4% from baseline at the 10 mg/kg IV dose, nadir occurring around day 3 to 5 post-dose [1]. All values remained within the normal laboratory range and returned to baseline without intervention.

P1NP increased in a clear dose-response pattern, peaking at 148% above baseline in the 10 mg/kg IV group by day 29 [1]. This confirms that supratherapeutic romosozumab exposure amplifies the anabolic signal but does not trigger a qualitatively different or dangerous physiological response.

No subject required calcium supplementation beyond what was already provided. No cardiac events, thromboembolic events, or hypersensitivity reactions were reported at any dose tier.

Pharmacokinetics Relevant to Overdose

Romosozumab follows nonlinear (target-mediated) pharmacokinetics. After a 210 mg subcutaneous dose, the median time to peak concentration (Tmax) is approximately 5 days. The steady-state half-life is about 12.8 days [4]. Because clearance is partly mediated by binding to sclerostin itself, higher doses do not produce proportionally higher or longer exposures; the system partially self-buffers.

Bioavailability after subcutaneous injection is estimated at 81% [4]. A patient who receives 420 mg SC (an accidental double dose) would therefore achieve approximately double the Cmax, but the half-life would not extend dramatically because target-mediated disposition accelerates at higher concentrations.

Romosozumab is not expected to be dialyzable. Hemodialysis membranes do not clear large monoclonal antibodies effectively. Plasmapheresis could theoretically reduce circulating drug levels but has never been studied or clinically warranted for romosozumab overdose.

Accidental Double Dose: Clinical Scenario and Management

The most realistic overdose scenario is a patient who forgets whether this month's injection was given and receives a second 210 mg dose within the same 30-day cycle. Based on Phase I data, this exposure (420 mg SC) falls well within the range already tested in humans without dose-limiting toxicity.

The prescribing information does not provide explicit guidance for this situation. The Endocrine Society and AACE recommend a practical approach consistent with the drug's monthly dosing interval: skip the next scheduled dose entirely and resume the normal monthly schedule after that [2]. This effectively restores the intended cumulative 12-month exposure (approximately 2,520 mg total) with minimal deviation.

Monitoring checklist after accidental double dose

Clinicians should obtain the following within 48 to 72 hours of the excess dose:

1. Serum calcium (total and ionized) to screen for hypocalcemia
2. Serum 25-hydroxyvitamin D to identify patients at greatest risk of calcium drop
3. Serum albumin (to correct total calcium if needed)
4. Blood pressure and heart rate assessment
5. Review of symptoms: chest pain, jaw pain, extremity weakness, paresthesias, muscle cramps

If calcium is low-normal or below range, increase oral calcium carbonate or citrate supplementation to 1,200 to 1,500 mg daily and recheck in 5 to 7 days. If ionized calcium drops below 1.0 mmol/L or the patient becomes symptomatic (perioral tingling, carpopedal spasm, QTc prolongation), IV calcium gluconate 1 to 2 g over 10 minutes is appropriate [5].

The Cardiovascular Signal: Extra Caution After Excess Dosing

The ARCH trial (N=4,093) compared romosozumab to alendronate in postmenopausal women with osteoporosis and prior fracture. Romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months [6]. The trial also revealed an imbalance in adjudicated major adverse cardiovascular events (MACE): 50 events in the romosozumab group vs. 38 in the alendronate group during the 12-month open-label phase (hazard ratio 1.31, 95% CI 0.85 to 2.00) [6].

This signal prompted the FDA boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year. The mechanism behind the cardiovascular signal remains incompletely understood. Some researchers hypothesize that sclerostin inhibition may promote vascular calcification through activation of Wnt signaling in arterial smooth muscle cells [7].

After an accidental excess dose, the cardiovascular concern deserves specific attention. While a single supratherapeutic exposure is unlikely to trigger an acute cardiovascular event in an otherwise low-risk patient, the clinician should:

• Review the patient's baseline cardiovascular risk factors
• Obtain an ECG if the patient reports chest discomfort, dyspnea, or palpitations
• Measure blood pressure at the 48 to 72 hour follow-up visit
• Counsel the patient to seek emergency care for any new chest pain, unilateral weakness, or speech difficulty during the 2 weeks following the excess dose

Dr. Felicia Cosman, a leading osteoporosis researcher at Columbia University and an investigator in multiple romosozumab trials, stated in her 2020 review: "The cardiovascular signal in ARCH was not seen in the FRAME trial against placebo, suggesting the finding may reflect a protective effect of alendronate rather than a harmful effect of romosozumab" [8]. This interpretation does not eliminate the need for cardiovascular vigilance after overdose, but it does contextualize the risk.

Hypocalcemia: The Primary Biochemical Risk

Romosozumab stimulates rapid mineralization of new osteoid, pulling calcium and phosphate from the bloodstream into bone matrix. In the FRAME trial (N=7,180), the incidence of hypocalcemia was 0.4% in the romosozumab arm vs. 0.2% in placebo at 12 months [9]. All cases were transient and asymptomatic. The prescribing label requires correction of hypocalcemia before starting therapy and adequate calcium (at least 1,000 mg daily) plus vitamin D (at least 600 IU daily) supplementation throughout treatment.

Patients at highest risk of clinically significant hypocalcemia after an excess dose include those with:

• Baseline 25-hydroxyvitamin D levels below 20 ng/mL
• Chronic kidney disease (eGFR <30 mL/min) where 1,25-dihydroxyvitamin D production is impaired
• Concurrent use of loop diuretics, which increase renal calcium loss
• Malabsorption syndromes limiting dietary calcium uptake

The onset of the calcium nadir after a standard 210 mg dose is typically 3 to 5 days post-injection, based on Phase I observations [1]. After a double dose, clinicians should expect a potentially deeper and slightly earlier nadir. A follow-up calcium check at day 3 and day 7 is a reasonable monitoring cadence.

Special Populations and Overdose Considerations

Renal impairment

No dose adjustment is recommended for mild to moderate renal impairment. Romosozumab has not been studied in patients with eGFR <30 mL/min [4]. In this population, the capacity to mobilize calcium from the gut and kidneys is already compromised. An accidental excess dose carries a proportionally higher risk of symptomatic hypocalcemia. Consider inpatient observation for 24 to 48 hours if severe CKD is present.

Patients on concurrent denosumab or bisphosphonates

Some treatment algorithms involve transitioning from romosozumab to denosumab or a bisphosphonate to consolidate bone density gains. If a patient inadvertently receives both romosozumab and denosumab in the same month, the antiresorptive effects are additive. The risk of hypocalcemia is substantially increased in this dual-exposure scenario. The Endocrine Society 2019 clinical practice guideline recommends checking serum calcium within 1 to 2 weeks of any antiresorptive dose in high-risk patients [10].

Elderly patients (age ≥75)

The ARCH trial enrolled patients with a mean age of 74.3 years [6]. Subgroup analysis showed no differential safety signal by age. Older patients may, however, have lower baseline vitamin D stores and reduced renal function, compounding the hypocalcemia risk discussed above.

What Romosozumab Overdose Is Not

Romosozumab overdose is not analogous to overdose with small-molecule osteoporosis drugs. Oral bisphosphonate overdose can cause severe esophageal erosion, electrolyte disturbances, and renal failure. Teriparatide (Forteo) in massive excess theoretically raises the risk of hypercalcemia and osteosarcoma (though the latter was only demonstrated in rat models with lifetime-equivalent dosing) [11].

Romosozumab's safety profile at supratherapeutic doses reflects the biology of monoclonal antibody pharmacology. Antibodies rarely cause acute organ toxicity from concentration-dependent mechanisms. The main risks are target-mediated pharmacologic exaggeration (too much sclerostin inhibition, leading to too much calcium deposition into bone) and immune-mediated reactions (injection-site or systemic hypersensitivity). Neither has been observed at dangerous severity in any published romosozumab study.

Reporting and Documentation

Any suspected overdose should be documented in the patient's medical record with the date, estimated total dose received, and clinical findings. Healthcare providers in the United States should report adverse events, including overdose, to the FDA MedWatch program and to Amgen's pharmacovigilance department (1-800-772-6436). This reporting contributes to the post-marketing safety database that informs future labeling updates.

As of 2026, the FDA Adverse Event Reporting System (FAERS) does not contain published case reports of romosozumab overdose resulting in hospitalization or death.

Patients who have received an accidental excess dose should continue their remaining romosozumab course (after skipping one dose) unless their prescriber identifies a specific contraindication. Discontinuation of the entire 12-month course due to a single accidental double dose is not supported by available evidence and may compromise fracture risk reduction.

Frequently asked questions

›What should I do if I accidentally took two doses of Evenity in one month?

Contact your prescribing clinician. In most cases, the recommendation is to skip the next scheduled monthly dose and resume normal dosing after that. Have your serum calcium checked within 3 to 5 days of the extra dose.

›Can you overdose on romosozumab?

True overdose with romosozumab is extremely unlikely because it is administered as prefilled syringes with a fixed 105 mg dose. The most realistic scenario is receiving two monthly doses too close together. Phase I data show the drug was well tolerated at exposures 5 times higher than the standard dose.

›Is there an antidote for Evenity overdose?

No. There is no specific antidote or reversal agent for romosozumab. Management is supportive, focused primarily on monitoring and correcting serum calcium levels.

›What are the symptoms of romosozumab overdose?

Based on Phase I data, symptoms may include mild hypocalcemia (tingling around the mouth or fingertips, muscle cramps) and injection-site reactions. Severe toxicity has not been observed even at supratherapeutic doses.

›Can Evenity be removed by dialysis?

No. Romosozumab is a large monoclonal antibody (approximately 149 kDa) that is not effectively cleared by hemodialysis membranes.

›How does Evenity (romosozumab) work?

Romosozumab binds and inhibits sclerostin, a protein that normally slows bone formation. By blocking sclerostin, the drug simultaneously increases bone building by osteoblasts and decreases bone breakdown by osteoclasts, producing rapid gains in bone mineral density.

›What is the black box warning on Evenity?

The FDA boxed warning states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. It should not be used in patients who have had a heart attack or stroke within the previous 12 months.

›Does romosozumab cause heart attacks?

The ARCH trial found a numerical imbalance in cardiovascular events favoring alendronate over romosozumab, but the FRAME placebo-controlled trial did not replicate this signal. The question of whether romosozumab directly increases cardiovascular risk or whether alendronate is cardioprotective remains under investigation.

›How long does romosozumab stay in your system?

Romosozumab has a half-life of approximately 12.8 days. After the last dose, it takes roughly 64 days (about 5 half-lives) for the drug to be effectively eliminated from the body.

›What happens if you miss a dose of Evenity?

If you miss a scheduled dose, take it as soon as possible and then reschedule your next injection so it falls one month later. Do not double up doses to make up for a missed one.

›Can I take Evenity and Prolia at the same time?

They are not typically given concurrently. Romosozumab is usually given first for 12 months, followed by denosumab (Prolia) to maintain bone density gains. If both are accidentally administered in the same month, serum calcium should be checked within 1 to 2 weeks.

›Is Evenity safer than Forteo for osteoporosis?

Both drugs are anabolic agents with distinct safety profiles. Romosozumab carries a cardiovascular boxed warning, while teriparatide (Forteo) carries a warning about osteosarcoma based on animal data. Efficacy comparisons from the STRUCTURE trial suggest romosozumab produces greater hip BMD gains at 12 months.

References

1. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26
2. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, 2020 update. Endocr Pract. 2020;26(Suppl 1):1-46
3. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883-19887
4. Romosozumab-aqqg (Evenity) prescribing information. U.S. Food and Drug Administration. 2019
5. Cooper MS, Gittoes NJL. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298-1302
6. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis (ARCH). N Engl J Med. 2017;377(15):1417-1427
7. Brandenburg JJ, Kramann R, Godber B, et al. The Wnt pathway in vascular calcification. Arterioscler Thromb Vasc Biol. 2018;38(9):e174-e177
8. Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Bone. 2020;138:115489
9. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis (FRAME). N Engl J Med. 2016;375(16):1532-1543
10. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622
11. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321